Hologic, Inc. (HOLX) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Hologic, Inc. (NASDAQ:HOLX) have earned an average rating of “Buy” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $47.77.
Several brokerages have recently weighed in on HOLX. Bank of America Corporation reaffirmed a “neutral” rating and set a $48.00 price target (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price target on shares of Hologic in a report on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a report on Friday, July 14th. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Barclays PLC reissued an “overweight” rating and set a $53.00 target price (up previously from $50.00) on shares of Hologic in a report on Monday, July 17th.
COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Receives Consensus Recommendation of “Buy” from Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/11/02/hologic-inc-holx-receives-consensus-recommendation-of-buy-from-brokerages.html.
In other news, Director Lawrence M. Levy sold 9,596 shares of the company’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lawrence M. Levy sold 7,138 shares of the company’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $37.38, for a total value of $266,818.44. The disclosure for this sale can be found here. Insiders sold a total of 23,873 shares of company stock valued at $898,754 in the last 90 days. Corporate insiders own 0.79% of the company’s stock.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same period in the prior year, the business posted $0.51 EPS. Hologic’s revenue was up 12.4% on a year-over-year basis.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.